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Background: The incidence of bepridil-induced pulmonary toxicity, such as interstitial pneu-
monia, is still unknown. The aim of the present study was to evaluate the incidence of
bepridil-induced pulmonary toxicity.
Methods and results: A total of 253 patients treated with bepridil between January 2009 and
January 2011 were retrospectively evaluated. Eight out of the 222 evaluable patients (male/
female: 5/3, age range: 64e97 years, average age: 80.5 years, median age: 81.0 years) showed
bepridil-induced pulmonary toxicity.
Conclusions: The incidence of bepridil-induced pulmonary toxicity was 3.60% in our study pop-
ulation.
ª 2013 Elsevier Ltd. All rights reserved.address: 1-1 Iseigaoka,
07-8555, Japan. Tel.: þ81 93
-u.ac.jp (K. Yatera).
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13.09.023Introduction
Bepridil inhibits the Naþ, Kþ and Ca2þ channels in car-
diomyocytes, and exerts antiarrhythmic effects by reducing
the maximum depolarization rate of the atrial muscles,
atrioventricular node, ventricular muscles, etc. Bepridil
has been used for the treatment of atrial fibrillation, ven-
tricular tachyarrhythmia and angina pectoris. There have.
Bepridil-induced interstitial pneumonia 2089been several reported cases of bepridil-induced pulmonary
toxicity [1e3]; however, the incidence of bepridil-induced
pulmonary toxicity is still unknown. The aim of the pre-
sent study was to evaluate the incidence of bepridil-
induced pulmonary toxicity.
Methods
Patients
Two hundred fifty-three patients treated with bepridil be-
tween January 2009 and January 2011 at Saiseikai Yama-
guchi General Hospital were retrospectively evaluated.
Methods
The diagnosis of bepridil-induced pulmonary toxicity was
made according to the following criteria originally devel-
oped for the clinical diagnosis of amiodarone-induced pul-
monary toxicity [4]. Any two of the following findings: (1)
new or worsening symptoms; (2) new abnormalities or
worsening of chest roentogenograms; (3) a decline of at
least 15% in the diffusing capacity for carbon monoxide or
the total lung capacity, with the exclusion of other diag-
nostic possibilities (especially occult congestive heart fail-
ure), together with a reasonable constellation of symptoms
or findings consistent with the diagnosis. The incidence of
bepridil-induced pulmonary toxicity in the 222 evaluable
patients who had been treated with bepridil for at least one
year and who underwent chest X-rays and/or chest
computed tomography scans pre- and post-bepridil treat-
ment were analyzed with the clinical data by threeTable 1 Clinical characteristics of the study patients.
n 222
Male/Female 157/65
Age, years 73.9  11.0
Heart disease
Atrial fibrillation 140
Ischemic heart disease 119
Ventricular tachycardia 40
Valvular heart disease 23
Chronic heart failure 158
Cardiomyopathy 4
Comorbidities
Hypertension 173
Diabetes mellitus 74
Concomitant drugs
ACEI/ARB 111
Calcium-channel blocker 77
a,b-blocker 116
Diuretic 65
Aldosterone antagonist 35
Digoxin 14
Statin 53
Uricosuric agent 31
Antiplatelet agent 175
Radiographic findings
Interstitial pneumonia 0specialized respirologists. The outcomes and treatment of
the patients with bepridil-induced pulmonary toxicity were
also evaluated.Results
The average (median) age of the 222 evaluated patients
was 73.9 (76) years old, and the ratio of males/females was
157/65 (Table 1). Eight cases (male/female: 5/3, age
range: 64e97 years, average age: 80.5 years, median age:
81.0 years) showed bepridil-induced pulmonary toxicity,
making the incidence 3.60% in our population. All eight
patients demonstrated no remarkable abnormal chest X-ray
findings before the start of bepridil administration. The
latency to developing pulmonary toxicity after starting
bepridil treatment ranged from 14 days to 10 months
(average: 152 days, median: 195 days). All eight cases dis-
continued bepridil administration, and six out of these
eight patients received corticosteroids (starting dose of
prednisolone: 20e500 mg/day) in addition to the cessation
of bepridil. All eight cases showed improvement of the
pulmonary toxicity after the cessation of bepridil. In addi-
tion, the drug lymphocyte stimulation test (DLST) was
performed in three out of the eight patients, and all three
of these patients showed negative results.Discussion
This is the first study reporting the incidence of bepridil-
induced pulmonary toxicity, and the incidence was 3.60%
(eight out of 222 cases) in our patient population. Six prior
cases of bepridil-induced pulmonary toxicity had been re-
ported in the English literature [2], and one case of acute
interstitial pneumonia had also been reported as a side
effect in a randomized study of amiodarone and bepridil
out of the 20 patients in the bepridil-arm [5]. The diagnosis
of drug-induced pulmonary toxicities, including those due
to bepridil, is associated with uncertainties, largely
because of the restrictions regarding the re-challenge of
patients, and the diagnostic criteria we use are generally
non-specific. Therefore, the incidence in the present study
can only be considered a loose approximation at best.
We next compared the cases in the present study with
the other six reported cases of bepridil-induced interstitial
pneumonia (Table 2). All of the previously reported cases
were elderly males, had received doses ranging from
150 mg to 400 mg, had generally received treatment for
two weeks to two months prior to the development of
symptoms, but had developed symptoms up to 226 days
after beginning the treatment. Similar to the previous
cases, most of our patients were over 80 years old. In
contrast, our patients included three females out of the
eight total cases, and this is the first report of a female with
bepridil-induced pulmonary toxicity. Three patients
showed symptoms within two weeks after starting bepridil
administration in our present study, but five patients
demonstrated symptoms more than six months after start-
ing the treatment, and a longer duration of time to the
development of the pulmonary toxicity of bepridil was
suggested in our study than was reported previously.
Table 2 Demographic characteristics of patients with bepridil-induced pulmonary toxicity.
No. Age
(years)/
sex
Bepridil
dose
(mg/day)
Period to
development
(days)
Arrhythmia Therapy Treatment
response
KL-6 (U/ml) DLST Chest X ray
finding before
the start of
bepridil
CT
1 80 M 200 240 AF PSL 20 mg Improved 510 Negative None Bilateral reticular and ground-
glass shadow
2 83 F 200 210 AF PSL 20 mg Improved 857 Negative None Bilateral reticular and ground-
glass shadow predominantly in
the lower lung fields
3 82 M 100 180 AF PSL 20 mg Improved 477 (after
improvement)
N/A None Bilateral diffuse ground-glass
shadow predominantly in the
right lung fields
4 80 M 200 14 AF PSL 30 mg Improved N/A N/A None Right patchy shadow and
consolidations
5 97 F 100 240 AP Cessation
of bepridil
Improved N/A N/A None Bilateral reticular and ground-
glass shadow
6 83 F 200 22 AF mPSL 500 mg Improved N/A Negative None Bilateral ground-glass shadow
7 64 M 200 14 AF mPSL 20 mg Improved N/A N/A None Ground-glass shadow
predominantly in the right
upper lung field
8 75 M 100 300 VT mPSL 20 mg Unchanged N/A N/A None Bilateral ground-glass shadow
9 72 M 400 21 AF PSL 40 mg Improved Not reported Not reported Not reported Not reported
10 65 M 150 14 AF mPSL 500 mg
3days
Improved 692 Borderline Not reported Bilateral reticular and ground-
glass shadow predominantly in
lower lung field
11 66 M 200 30 AF PSL 30 mg Improved 287 Negative Not reported Bilateral reticular and ground-
glass shadow predominantly in
the lower lung fields
12 69 M 200 60 AF mPSL 1000 mg
3days
Improved 1230 Unknown Not reported Diffuse bilateral infiltrations
predominantly in the lower
lung field
13 72 M 200 40 AF Cessation of
bepridil
Improved 3960 Unknown Not reported Diffuse, centrilobular, small
granular infiltrations
predominantly in the lower
lung field
14 74 M 200 226 AF PSL 60 mg Improved 2745 Negative None Diffuse dense consolidations
predominantly peribronchial
distribution
AF: atrial fibrillation, AP: angina pectoris, DLST: drug-induced lymphocyte stimulation test, PSL: prednisolone.
mPSL: metylprednisolone, N/A: not analyzed, S.I.: stimulation index, VT: ventricular tachycardia.
#1e8: present cases, #9e14: reported cases.
2090
K
.
Y
a
m
a
sa
ki
e
t
a
l.
Bepridil-induced interstitial pneumonia 2091As reported previously, bilateral reticular and ground-
glass shadows and diffuse bilateral infiltrations were the
radiological findings of bepridil-induced pulmonary
toxicity. The DLST does not appear to be useful for diag-
nosing bepridil-induced pulmonary toxicity. The treat-
ment of bepridil-induced pulmonary toxicity is basically
the cessation of bepridil, with or without the systemic
administration of corticosteroids, although the role of
treatment, including corticosteroid treatment is still
unclear.
Generally, cytotoxicity and immunological activation are
considered to be the primary mechanisms leading to drug-
induced pulmonary toxicity. Amiodarone, which blocks the
same channels as bepridil, has been reported to be cyto-
toxic to alveolar epithelial cells and fibroblasts [6], to
induce an imbalance of TH1/Th2 lymphocytes [7], to induce
TNF-alpha and-beta from alveolar macrophages [8] and to
activate the angiotensin system [9], but the mechanism
underlying the development of pulmonary toxicity due to
bepridil are still unknown.
With respect to the ethnic differences in amiodarone-
induced pulmonary toxicity between Asian subjects and
those of other ethnicities, the reported incidence of
amiodarone-induced pulmonary toxicity has varied
widely, mainly due to the differences in the investigation
methods and the doses of amiodarone. The reported
incidence of amiodarone-induced pulmonary toxicity was
2.98% (10/336) compared to 1.18% in the placebo group in
a US double-blind, placebo-controlled study of patients
with mild-to-moderate heart failure receiving amiodar-
one (300e800 mg/day) [10]. On the other hand, a rela-
tively high incidence of amiodarone-induced pulmonary
toxicity in Japanese patients (10.6%) was reported in a
retrospective study that evaluated 500 consecutive pa-
tients receiving low-dose amiodarone, with mean a
follow-up period of 48 months and a mean maintenance
dose of 141 mg/day [11]. Although the molecular mech-
anism(s) underlying the drug pulmonary toxicity is un-
clear, East-Asian ethnicity, including Japanese ethnicity,
may be associated with a higher incidence of
amiodarone-induced pulmonary toxicity, along with other
drug-induced pulmonary toxicities, such as that due to
gefitinib [12].Conclusion
The incidence of bepridil-induced interstitial pneumonia
was 3.60% in our study population, and all cases showed
improvement of the interstitial pneumonia after discon-
tinuation of bepridil, with or without corticosteroid
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